ATLAS-2M, Wk 96 Results: Long-Acting Injectable Cabotegravir + Rilpivirine Every 8 Wks Is Noninferior to Every 4 Wks

Expert selections of data for state-of-the-art switch strategies in virologically suppressed patients.

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Paul E. Sax, MD Released: May 6, 2022

Slides from CCO: Discussion of key data and recommendations for the use of novel therapies for HIV treatment and prevention

Cristina Mussini, MD William R. Short, MD, MPH, AAHIVS Released: April 15, 2022

Expert selections of cutting-edge HIV data, including the latest on long-acting therapies and pre-exposure prophylaxis

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Darcy Wooten, MD Released: March 25, 2022

Dr. Babafemi Taiwo discusses the latest Week 152 data on LA CAB plus RPV from ATLAS-2M presented at CROI 2022, reported by Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: March 15, 2022